이 기사의 번역을 준비하고 있습니다. 그동안 영어 원문을 임시로 표시합니다.
비즈니스 · 2026. 2. 13.1 분 읽기
Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases
로컬 자동 번역 · 원본 출처 언어
요약
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice to Kyverna Therapeutics, Inc. ("Kyverna"), a company located in Emeryville, California, the United States of America.
원본 출처 언어: Federal Register — Health and Human Services원문 발표 열기 →